1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA
To Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology, Investor Presentation
Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Annual Report to Security Holders
Amendment No. 3 to Equity Distribution Agreement with Piper Sandler
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
Investor Presentation
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Submission Upload
Correspondence